Overview

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Interferon-alfa-1b
Interferon-alpha
Interferons